1stOncology™: Cancer Intelligence Service – Page 8 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

On August 11, 2026 Tango Therapeutics, Inc. (NASDAQ: TNGX) (Tango or the Company), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported financial results for the second quarter ended June 30, 2026, and provided business highlights.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

"The second quarter marked a pivotal period for Tango, with milestones that validated our PRMT5 inhibitor pipeline and reflect the progress of our maturing organization. Notably, initial Phase 1/2 data showed vopimetostat plus daraxonrasib achieved a 92% objective response rate with encouraging durability in MTAP-deleted, RAS-mutant pancreatic cancer, giving us the confidence to move this combination rapidly into Phase 3 development for patients," said Malte Peters, MD, Chief Executive Officer of Tango. "As the Company transitions from a research-led organization into one positioned to bring vopimetostat to patients, our focus for the second half of the year remains on defining the registrational path for vopimetostat in front-line pancreatic cancer and providing updates from our broader pipeline. I am pleased with the progress we have made against executing on our clinical development plan, which is well on track, and the team continues to be laser-focused on bringing vopimetostat to patients as soon as possible. With our robust balance sheet, our cash runway carries us through our planned development and commercialization preparation in pancreatic cancer, as well as ongoing work across our pipeline."

Clinical Pipeline Updates

Vopimetostat – MTAP Selective Once-Daily PRMT5 Inhibitor

In June, Tango reported initial data from vopimetostat in combination with Revolution Medicines’ RAS(ON) inhibitors daraxonrasib or zoldonrasib in patients with MTAP-deleted, RAS-mutant pancreatic cancer. Data demonstrated that vopimetostat in combination with daraxonrasib achieved a 92% objective response rate and 90% six-month progression-free survival rate in this patient population, with a generally well-tolerated safety profile.
Based upon the positive Phase 1/2 data, Tango is working internally and has initiated dialogue with regulators and its collaborator Revolution Medicines toward the goal of developing a registrational plan and path forward for vopimetostat plus daraxonrasib in MTAP-deleted pancreatic cancer.
The Company plans to share data from the Phase 1/2 trial of the combination of vopimetostat plus RAS(ON) inhibitors at the 2026 European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress in Madrid, Spain from October 23-27, 2026.

Corporate Updates

Executive Leadership. Today, the Company announced that it has appointed Fatma Ocak to the role of Chief Commercialization Officer, effective August 17, 2026. In this role, Ms. Ocak will oversee all aspects of launch readiness and oversee key functions, including medical affairs, commercial strategy, and clinical and commercial integration. Prior to joining Tango, she served as Senior Vice President and General Manager, US Oncology at BioNTech. Previously, she held senior executive roles at Novartis across both global and US oncology leadership, driving strategic product positioning, market access, and commercial execution. Throughout her 25-year career in pharmaceuticals, she has specialized in bridging research and development to competitive market execution.
Board of Directors. In June, the Company strengthened its Board of Directors with the appointment of Robert Azelby, adding more than 30 years of biopharmaceutical leadership experience in oncology commercialization and corporate strategy as Tango prepares to advance vopimetostat into late-stage clinical development. On August 6, 2026, Mr. Azelby was appointed Chairman of the Tango Board of Directors.

Upcoming Expected Milestones

Present Phase 1/2 data of vopimetostat in combination with RAS(ON) inhibitors at the 2026 ESMO (Free ESMO Whitepaper) Congress in Madrid, Spain from October 23-27, 2026
Finalize design of Phase 3 randomized-controlled trial of the combination approach in front-line pancreatic cancer in 2H 2026
Disclose vopimetostat lung cancer monotherapy data in 2H 2026
Release initial TNG456 data in glioblastoma and other cancers in 2H 2026
Initiate Phase 1/2 vopimetostat + ERAS-0015 (Erasca) combination study in 2H 2026

Financial Results

As of June 30, 2026, the Company held $1.0 billion in cash, cash equivalents and marketable securities, which the Company expects to fund its current operating plan.

Collaboration revenue was $0 for the three months ended June 30, 2026, compared to $3.2 million for the same period in 2025, and $0 for the six months ended June 30, 2026, compared to $8.6 million for the same period in 2025. All remaining deferred revenue from the upfront and research option-extension payments under the Gilead collaboration was recognized as collaboration revenue during the year ended December 31, 2025 as a result of the truncation of the collaboration agreement which concluded all research activities.

Research and development expenses were $37.2 million for the three months ended June 30, 2026, compared to $32.8 million for the same period in 2025, and $70.7 million for the six months ended June 30, 2026, compared to $69.2 million for the same period in 2025. The change was primarily due to increased spend related to the advancement of the vopimetostat and TNG456 clinical programs. This increase was partially offset by decreased spend resulting from the impact of our portfolio prioritization efforts.

General and administrative expenses were $22.6 million for the three months ended June 30, 2026, compared to $11.3 million for the same period in 2025, and $37.8 million for the six months ended June 30, 2026, compared to $22.8 million for the same period in 2025. The increase was primarily due to increased spend on personnel-related costs, including share-based compensation expense.

Net loss for the three months ended June 30, 2026 was $55.3 million, or $0.37 per share, compared to a net loss of $38.9 million, or $0.35 per share, in the same period in 2025. Net loss for the six months ended June 30, 2026 was $100.9 million, or $0.68 per share, compared to a net loss of $78.7 million, or $0.71 per share, in the same period in 2025.

(Press release, Tango Therapeutics, AUG 11, 2026, View Source [SID1234669979])

Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma

On August 11, 2026 Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, reported the selection of a dose of 0.60 mg/m2 that will be employed in future for all patients randomized to receive EIK1001 in the TeLuRide-006 trial. This decision aligns with a recommendation from an independent DMC following a prespecified analysis of unblinded data.

"To date, despite multiple combination clinical studies, statistically significant improvement in overall survival in the treatment of advanced melanoma has not been achieved over checkpoint inhibitor monotherapy," said Roy Baynes, M.D., Ph.D., Chief Medical Officer of Eikon. "EIK1001’s activation of both myeloid and plasmacytoid dendritic cells to stimulate both innate and adaptive immunity, bringing a broader répertoire of immune cells to target tumor cells, represents both an orthogonal mechanism and an agent with monotherapy activity. These criteria merit study in combination with checkpoint inhibitors. The selection of an optimized dose for this trial advances our efforts to bring this approach to patients in urgent need of better therapies."

(Press release, Eikon Therapeutics, AUG 11, 2026, View Source [SID1234669978])

Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth

On August 11, 2026 Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, reported financial results for the second quarter ended June 30, 2026 and provided a business update, including strategic leadership transitions marking the company’s next era of execution and growth.

Ryan Cohlhepp, Pharm.D., Bicara’s President and Chief Operating Officer (COO) will succeed Claire Mazumdar, Ph.D., MBA as Chief Executive Officer (CEO) effective January 1, 2027. As part of this planned evolution in leadership, Dr. Mazumdar will serve as Vice Chair of the Board of Directors and Strategic Advisor, with the goal of ensuring a seamless transition as Bicara enters its next era of execution and growth. Dr. Mazumdar will leverage her deep institutional knowledge to provide management guidance and support future growth, while empowering the next phase of strategic and operational leadership at Dr. Cohlhepp’s direction as the company prepares for the potential commercialization of ficerafusp alfa in first-line (1L) recurrent or metastatic (R/M) human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC), with topline data from an interim analysis of the FORTIFI-HN01 pivotal trial expected in mid-2027.

Tanya Green, Chief Development Officer, will succeed Dr. Cohlhepp as COO, effective January 1, 2027. Since joining Bicara in October 2025, Ms. Green has demonstrated enterprise-wide responsibility for driving operational strategy, execution, and organizational performance across key development and operational functions including global clinical operations, technical operations, regulatory affairs, quality, and program management.

Jenn Larson, CPA, has been appointed Chief Financial Officer and will succeed Ivan Hyep, MBA, effective August 12, 2026. Ms. Larson is a tenured financial operator who brings decades of experience in roles of increasing strategic and operational responsibility at publicly traded, revenue-generating, commercial-stage biotechnology organizations.

Jenna Cohen will be promoted from Chief Corporate Affairs Officer to Chief Business Officer, effective January 1, 2027. Ms. Cohen has demonstrated an increasing scope of strategic and executional impact since joining Bicara in October 2025, and in her new role will retain oversight of corporate affairs, corporate development, and strategy.

Greg Shiferman, J.D., has been appointed Chief Legal Officer effective August 31, 2026. Mr. Shiferman is an accomplished life sciences professional who has served in executive positions across legal and program leadership. Mr. Shiferman brings deep experience providing strategic counsel across corporate development, commercialization, and governance. He will lead all aspects of our legal and compliance functions through key corporate milestones, including the potential commercial launch of ficerafusp alfa.
"This transition marks a natural evolution for Bicara as we maintain strong enrollment momentum that enables a clear line of sight to a topline interim analysis which we believe will lead to an accelerated approval and subsequent launch of ficerafusp alfa in head and neck cancer. I am incredibly proud of what our team has accomplished so far—transforming bold science into meaningful impact for patients while establishing a strong foundation for future growth. Having worked closely with Ryan since Bicara’s earliest days, I have seen firsthand his ability to translate strategy into disciplined execution, and we have been true partners in shaping the Bicara of today. I have complete confidence that he is the right leader to guide our next chapter," said Claire Mazumdar, Ph.D., MBA, Chief Executive Officer of Bicara Therapeutics. "In addition, I want to thank Ivan for serving as an early executive at Bicara, for leading us through private and public offerings during his tenure, and for establishing the early infrastructure for the Finance organization. In my new role, I look forward to continuing to help shape the future of Bicara—both on the Board and supporting the leadership team as they build on this momentum and continue creating lasting value for patients, employees, and shareholders."

"On behalf of the Board, I want to thank Claire for her extraordinary vision, leadership, and commitment to building a company defined by scientific excellence, a deeply rooted culture, and an unwavering focus on patients. Throughout her tenure, Claire has led with a long-term perspective, and this leadership transition reflects her thoughtful stewardship and commitment to Bicara’s continued success," said Mike Powell, Chairman of the Board of Bicara Therapeutics. "The Board has great confidence in Ryan to lead Bicara into its next era of execution and growth. This transition also reflects the investments we have made to prepare for our next chapter—including strengthening our executive team with experienced commercial leaders, elevating outstanding internal talent, and expanding the Board with directors who bring deep operational and commercialization expertise. Together, these steps have created a management team equipped to execute on the significant opportunities ahead, position the company for its next stage of growth, and broaden Bicara’s impact for patients."

"It is an incredible privilege to lead Bicara at such an important moment in its journey. Since the early days of Bicara, I have had the opportunity to help shape our strategy, help build the organizational capabilities and leadership team at the appropriate time in the company’s evolution, and work alongside an extraordinary group of colleagues to bring the tremendous promise of ficerafusp alfa to many people around the world through our clinical trials," said Ryan Cohlhepp, President and COO. "I am deeply grateful to Claire for her partnership and unwavering commitment to the ongoing success of this organization, and to the Board for its confidence in me. As we look ahead, my focus will be on building on the exceptional foundation we have created together—establishing our commercial footprint, advancing a pipeline with discipline and purpose, and continuing to invest in the people and culture that make Bicara unique."

Leadership biographies may be accessed on the Bicara website.

Second Quarter 2026 Highlights and Recent Progress

Ficerafusp Alfa in 1L R/M HPV-Negative HNSCC

Initiated FORTIFI-FLEX, a randomized, open-label, clinical study that will evaluate ficerafusp alfa in combination with pembrolizumab, administered as a 12-week loading dose of 1500mg weekly (QW) followed by maintenance dosing of 2250mg every three weeks (Q3W). The company expects to have results from this study by the time of a potential U.S. accelerated approval in 1L R/M HPV-negative HNSCC.
Presented extended follow-up data out to three years from the Phase 1/1b study of ficerafusp alfa in combination with pembrolizumab in 1L R/M HPV-negative HNSCC at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting. The data demonstrated deep, durable responses representing substantial improvements over standard of care treatment, observed to be driven by TGF-β inhibition, allowing for direct tumor penetration. Specifically, three-year follow-up from the 1500mg QW dose cohort showed an estimated OS rate of 31%, approximately doubling the survival rate observed in retrospective analysis with standard of care pembrolizumab in HPV-negative patients.
Key Anticipated Upcoming Milestones

HNSCC

Continued to enroll Phase 3 of the FORTIFI-HN01 pivotal trial in 1L R/M HPV-negative HNSCC and expect to be substantially enrolled by the end of the year to enable topline results from an interim analysis in mid-2027.
Other Solid Tumors, Including mCRC

Present data from Phase 1b expansion cohort evaluating ficerafusp alfa both as monotherapy and in combination with pembrolizumab in patients with 3L+ mCRC (RAS/BRAF wild type MSS) in the second half of 2026.
Second Quarter 2026 Financial Results

Cash, Cash Equivalents and Marketable Securities: As of June 30, 2026, Bicara had cash, cash equivalents and marketable securities of $497.3 million, compared to $414.8 million in cash, cash equivalents and marketable securities as of December 31, 2025. Based on its current operating and development plans, the company expects that its existing cash, cash equivalents and marketable securities will fund operations into the first half of 2029.
Research and Development Expenses: Research and development expenses were $45.8 million for the second quarter of 2026 as compared to $24.8 million for the second quarter of 2025. The increase was primarily due to costs associated with the ongoing FORTIFI-HN01 pivotal trial, as well as the company’s ongoing Phase 1/1b dose expansion cohorts, and an increase in personnel costs.
General and Administrative Expenses: General and administrative expenses were $14.2 million for the second quarter of 2026 as compared to $7.2 million for the second quarter of 2025. The increase was primarily due to additional personnel costs and professional fees associated with expanding the organization as we advance in a pivotal study and prepare for potential commercialization.
Net Loss: Net loss totaled $55.4 million for the second quarter of 2026 compared to $27.4 million for the second quarter of 2025.
Upcoming Investor Conference

Bicara Therapeutics will participate in one upcoming investor conference:

2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 9:10 a.m. ET.
A live webcast of the fireside chat will be accessible through the Investor Relations section of Bicara’s website under Events and Presentations. A replay of the webcast will be archived and available for 30 days following the event.

Conference Call Information

Bicara will host a live conference call and webcast at 8:30 a.m. ET today to discuss second quarter 2026 financial results and business updates, including strategic leadership transitions. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and a unique PIN that will allow them to access the call. An audio webcast will be accessible through the Investor Relations section of Bicara’s website under Events and Presentations. An archived replay will also be available for 30 days following the event.

(Press release, Bicara Therapeutics, AUG 11, 2026, View Source [SID1234669977])

Gibson Oncology Announces First Patient Completes Initial Treatment Cycle in Phase II Trial of LMP744 for Recurrent Glioblastoma

On August 11, 2026 Gibson Oncology, a clinical-stage oncology company developing blood-brain-barrier-penetrant therapies for brain tumors and other difficult-to-treat cancers, reported that the first patient in the Phase II clinical trial of LMP744 has been enrolled and has completed the initial treatment cycle without complication. The trial is being conducted by investigators at the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health, and is evaluating LMP744 as a single agent in patients with recurrent glioblastoma (GBM). Gibson Oncology is providing partial funding and LMP744 to the trial under a Clinical Cooperative Research and Development Agreement (CRADA) with NINDS.

LMP744 is a novel, dual-acting anticancer agent that works by reducing overexpression of the cMyc oncogene and by inhibiting topoisomerase 1 (TOPO1), two validated targets across a range of solid and hematological cancers.

Glioblastoma is the most common and aggressive primary brain tumor in adults. Approximately 13,000 new cases are diagnosed in the United States each year, median survival is generally 15 to 18 months, and the five-year survival rate is under 10 percent. Recurrent glioblastoma, for which there is no established standard of care, carries an especially poor prognosis.

In preclinical studies, LMP744 crossed the blood-brain barrier and achieved brain concentrations approximately 10 times the level needed to kill cancer cells, with a half-life in the brain exceeding 24 hours for each dose. Blood-brain-barrier penetration has long been one of the central obstacles in the treatment of brain tumors.

The Phase II trial is designed to enroll a total of 40 first-time recurrent GBM patients with a Karnofsky Performance Status (KPS) of 60 or better, with a primary endpoint of progression-free survival and a secondary endpoint of overall survival. LMP744 is being studied as a single therapeutic agent based on the strong anticancer effects observed in GBM patient-derived xenograft (PDX) animal models.

LMP744 has previously completed one Phase I clinical trial with 36 patients in heavily pretreated cancer patients, many of whom had failed as many as eight prior individual or combination treatments. Over 30% of the patients on single agent treatment with LMP744 experienced stable disease for up to 30 months and 2 patients were partial responders, even as many patients were sub-optimally dosed to establish the drug’s safety and tolerability before reaching the therapeutic dose level of 190 mg/m2.

"Completing the first treatment cycle in this trial is an important early milestone for LMP744 and, most of all, for the patients who face recurrent glioblastoma with limited therapeutic options, and one of the most difficult cancers in medicine," said Randall Riggs, President and Chief Executive Officer of Gibson Oncology. "We are grateful to the clinical team at NINDS and to the patients and families taking part in this study, and we look forward to advancing LMP744 as a potential breakthrough treatment in an area that has experienced little improvement in treatment options for decades."

Mr. Riggs continued, "The renewed excitement about LMP744 is two-fold. First, LMP744 was found to migrate rapidly into the brain at high concentrations, well beyond the levels needed to kill cancer, with each dose having a half-life of over 24 hours. Second, in PDX animal models implanted with patient-derived recurrent gliomas, just five doses of LMP744 produced tumor eradication. Together, these findings made a compelling case for initiating this Phase II study at the NINDS."

About LMP744

LMP744 is a novel, dual-acting indenoisoquinoline that reduces cMyc overexpression and inhibits topoisomerase 1 (TOPO1). In preclinical studies, it has demonstrated blood-brain-barrier penetration and sustained brain exposure. LMP744 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for all gliomas, including DIPG.

(Press release, Gibson Oncology, AUG 11, 2026, https://www.globenewswire.com/news-release/2026/08/11/3342662/0/en/gibson-oncology-announces-first-patient-completes-initial-treatment-cycle-in-phase-ii-trial-of-lmp744-for-recurrent-glioblastoma.html [SID1234669976])

SL Science Leadership Co-Authors Peer-Reviewed Framework for Clinical Development of γδ T Cell Therapy in Glioblastoma

On August 11, 2026 SL Science Holding Limited ("SL Science" or the "Company") (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and gene therapies, reported the publication of a peer-reviewed article in Biomedicines. Co-authored by SL Science leadership and clinical researchers from Taipei Medical University, the article outlines a rigorous development framework for γδ T cell therapy in glioblastoma –a common and aggressive primary brain cancer in adults. Beyond reviewing existing literature, the paper outlines the specific clinical trial designs, biological measurements, and testing conditions required to rigorously evaluate γδ T cell therapies in future human trials.

Strategic Impact on SL Science’s Business and Research

The publication serves as an industry roadmap while validating SL Science’s overarching business strategy and research direction. Glioblastoma remains notoriously difficult to treat because tumors rapidly mutate and evade traditional therapies aimed at a single target. In contrast, γδ T cells recognize cancer through universal stress signals rather than single antigens, target the stem-like cells responsible for tumor recurrence, and carry a low risk of graft-versus-host disease. This unique biology makes them suited for allogeneic, "off-the-shelf" manufacturing from healthy donors and repeated localized delivery directly to the brain, which is a model that directly mirrors SL Science’s FDA Drug Master File-backed platform. By publishing this framework alongside clinical researchers, SL Science establishes a clear standard of evidence for its own pipeline, supporting the design of future clinical programs to evaluate whether cells successfully reach, persist, and function within the tumor.

Translating Lab Science into Clinical Reality

To bridge the gap between promising laboratory data and actual patient outcomes, the framework outlines key operational shifts for clinical research. The authors stress that early-phase trials must embed quantitative cell-tracking and serial pharmacodynamic sampling to determine whether a treatment outcome is driven by cellular delivery, persistence, or functional exhaustion. Furthermore, cellular potency must be tested under realistic, low-oxygen and low-glucose tumor conditions rather than ideal laboratory environments. The article also supports direct, repeated delivery to the tumor cavity as a practical method to overcome the blood-brain barrier, while cautioning that trial endpoints should focus on verifiable biological activity before attempting to prove overall survival benefits in small, early-stage cohorts.

Management Commentary

"Glioblastoma has repeatedly defeated therapies that looked convincing in preclinical models. The clear lesson is that progress depends on rigorous evidence generation in humans, not further laboratory speculation," said Mr. William Wang, Chairman and Chief Executive Officer of SL Science. "This publication defines what we believe the next phase of development must look like: clinical trials designed from day one to show whether these cells reach the tumor, remain viable, and execute their therapeutic function. Translating this science into actionable clinical proof is our core focus, and our technology is advancing and evolving alongside new clinical discoveries. We intend our own programs to meet the exact standard we have set out here."

Clinical Context and Regulatory Disclosures

The article maintains a transparent assessment of current clinical evidence, noting that γδ T cell therapy in glioblastoma remains investigational. The publication represents an independent narrative review co-authored by company leadership in their personal scientific capacities; it received no external funding, was conducted independently of any commercial product, and does not evaluate or endorse any specific proprietary SL Science candidate.

(Press release, SL Science, AUG 11, 2026, View Source [SID1234669975])